Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
Elevance is the largest Blue Cross Blue Shield (BCBS) licensee in the US (14 states), giving it brand-protected, state-level managed care contracts that competitors cannot replicate. The Carelon services arm (analytics, pharmacy, behavioral, post-acute) is the UNH-Optum analog and is the growing half: in Q3 2026, the insurer's seasonal low, Carelon's operating gain of ~$0.9B (+17%) was about twice Health Benefits' $436M (-27.5%, 1.0% margin), though over nine months Health Benefits still earned more (~$3.5B vs ~$2.9B). It remains smaller and less integrated than Optum.
Elevance's competitive position rests on regulatory lock-in (state-level Medicaid contracts + BCBS branding), bilateral provider network effects, and proprietary claims data on 47M+ medical members:
- BCBS License: A Brand-Protected Geographic Monopoly: Elevance holds exclusive BCBS licenses in 14 states (CA, NY, GA, OH, IN, KY, VA, WI, CO, CT, ME, MO, NV, NH). The BCBS brand carries decades of provider trust and member familiarity that single-state plans cannot match. Switching out of an Elevance BCBS plan typically means switching out of the BCBS network — a meaningful behavioral and clinical disruption for members.
- State Medicaid + Medicare Advantage Contracts: Elevance administers Medicaid managed care in many of its BCBS states under multi-year capitation contracts that require state-specific licensure, actuarial certification, and network adequacy compliance. Each contract represents 3-5 years of regulated revenue with built-in renewal mechanisms; exit is operationally and politically difficult. Medicare Advantage contracts add another federal-program embedding layer.
- Carelon: The Healthcare Services Build: Carelon (formerly IngenioRx + various M&A) is Elevance's pharmacy benefit, analytics, behavioral health, and post-acute services platform. Carelon Services and Carelon Rx now generate ~$60B+ of segment revenue and are growing faster than the legacy Health Benefits business. The strategy mirrors UNH's Optum playbook with a 5-7 year lag; the directional thesis is sound but execution risk is real.
- Claims Data on 47M+ Members: Decades of claims data across 47M+ medical members and additional pharmacy/dental/vision lives feed risk-adjustment models, care management programs, and underwriting. While the dataset is meaningfully smaller than UNH's 140M-member base, it is still a structural asset for population health analytics and value-based care contracting in BCBS states.
Moat Verdict
Elevance's lock is still BCBS exclusivity in 14 states, Medicaid contracts, and the provider network. Those are AI-resilient. The May stamp had every resilient pillar at strong and printed 100, which put a Blue-plan insurer next to Moody's. Proprietary data is intact (47M vs UNH 140M). Bundling is weakened (Carelon is a lag, not Optum). Moat 90 sits just under UNH at 91. Growth and valuation stay. Coverage only. Not a print restamp.
77.6 resilient · 56.9 vulnerable · 80/20 = 73.5 · = 73
Open a moat to read its note.
Provider portals, claims submission systems, and Carelon care-management workflows accumulate years of organizational learning across hospital systems, physician groups, and HR benefits teams. Switching adds material retraining cost across thousands of users.
Risk-adjustment models, actuarial pricing, network-adequacy algorithms and Carelon clinical-decision tools are tuned to Elevance's BCBS state populations and government-program rules. UnitedHealth, Cigna, Humana and Centene run the same kinds of models, and no figure shows Elevance's are better, so it rates intact.
Carelon uses some publicly available CMS and NIH datasets in its analytical products, but Elevance's data advantage is private claims data on 47M+ members, rated under proprietaryData. It never held a public-data-access moat, so the pillar is not applicable rather than weakened. Previously weakened.
Healthcare actuaries, BCBS-license-trained underwriters, and clinical informaticists are genuinely scarce. Elevance is one of the largest employers of MA-experienced actuaries in the US, though the talent base is smaller than UNH/Optum's.
Health Benefits + Carelon Rx + Carelon Behavioral + Carelon Services is a vertical build, not Optum. The card already called it a 5–7 year lag with execution risk. Employers and state agencies can still unbundle PBM, behavioral, and analytics. Directionally similar to UNH, not peer-equal.
47M+ medical members generate decades of claims data that power risk-adjustment and care-management analytics. That is a real dataset. It is not UNH's 140M-member base. Marked intact, not strong, so ELV does not sit above UNH on data gravity.
BCBS license exclusivity in 14 states is a brand-protected regulatory monopoly within those geographies — the BCBS Association's licensing framework restricts which entity can use the brand in each state, effectively granting Elevance a multi-decade BCBS franchise in its footprint. State Medicaid managed-care contracts add multi-year regulated revenue with high re-licensure barriers. Federal MA contracts add another layer.
Bilateral provider-employer network effects: Elevance's 1.7M+ provider relationships in BCBS states make it the broadest network for employers in those geographies, and providers cannot afford to be out-of-network for the dominant BCBS plan in their state. Decades of network compounding create real switching friction on both sides.
Carelon Rx, claims processing, utilization management and care coordination run inside employer, hospital, Medicaid and Medicare Advantage operations. Employers and states re-bid insurers on multi-year cycles, and no retention figure is on file, so it rates intact — the same rating UnitedHealth carries.
Elevance's claims systems are the record of member health and financial transactions across 47M+ lives, and Carelon's care-management and behavioral-health platforms hold clinical records in provider practices in BCBS states. But every insurer's claims system is the record for its own members; that is table stakes, not a record third parties reconcile against. UnitedHealth rates strong on this pillar because Change Healthcare's clearinghouse touches roughly one in three US patient records across payers; Elevance has no equivalent cross-payer position. Re-rated from strong to intact.
Blue plan membership concentration secures provider discounts in its states, but UnitedHealth runs a larger national book.
Franchise reputation matters but is inseparable from the regulatory standing and relationships rated elsewhere; not credited twice.
Moat in 5–10 years
Elevance's moats hold. The BCBS licence in 14 states and the provider network that comes with being the dominant local plan are franchise positions that MA rate pressure and reserve questions do not touch. Carelon's bundle stays weakened and is a 5-7 year build with no attach figure yet, so no widening is called.
No moat trending · 73 holds
Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
Elevance is the largest Blue Cross Blue Shield (BCBS) licensee in the US (14 states), giving it brand-protected, state-level managed care contracts that competitors cannot replicate. The Carelon services arm (analytics, pharmacy, behavioral, post-acute) is the UNH-Optum analog and is the growing half: in Q3 2026, the insurer's seasonal low, Carelon's operating gain of ~$0.9B (+17%) was about twice Health Benefits' $436M (-27.5%, 1.0% margin), though over nine months Health Benefits still earned more (~$3.5B vs ~$2.9B). It remains smaller and less integrated than Optum.
Growth Score
Q3 2026 (reported October 21, 2026) operating revenue of $50.4B grew 0.7% YoY, after +1.5% in Q1 and +0.8% in Q2, as Health Benefits revenue (+2.6% to $43.4B on premium yields) offset medical membership of ~44.9M, down 1.1% YoY, with Medicare Advantage down 15.5% to 1.9M and Medicaid down 4.9% to 8.2M. The benefit expense ratio improved 70bps YoY to 90.6% on better Medicare Advantage and Individual ACA performance, but the adjusted operating expense ratio rose 90bps to 11.3% on one-time capability investments, and Health Benefits operating gain fell 27.5% to $436M (1.0% margin). Carelon revenue grew 5% to $19.3B (Q1 +7.9%, Q2 +6%) while its operating gain rose 17% to ~$0.9B. Adjusted EPS of $6.99 included a $1.85 net non-operating benefit. FY2026 adjusted EPS guidance rose to at least $29.00, but the recurring earnings baseline, which excludes non-recurring investment income, other non-operating items and targeted one-time investments, rose only $0.75 to at least $26.75; management targets at least 12% adjusted EPS growth from that baseline in 2027, about $30, roughly the $30.29 earned in 2025.
Valuation Score
At ~$440 ELV trades slightly above our $430 base case, about 15× the at-least-$29 FY2026 adjusted EPS guide but about 16× the $26.75 recurring baseline, which is the better earnings anchor because the guide includes non-operating gains. The price now sits between base and bull: it assumes the 12% growth target for 2027 is met, which would only take EPS back to about its 2025 level. The $935M risk-adjustment accrual and Medicaid rate adequacy are the remaining swing factors.
The BCBS Anchor + Carelon Build
Elevance's competitive position rests on regulatory lock-in (state-level Medicaid contracts + BCBS branding), bilateral provider network effects, and proprietary claims data on 47M+ medical members:
- BCBS License: A Brand-Protected Geographic Monopoly: Elevance holds exclusive BCBS licenses in 14 states (CA, NY, GA, OH, IN, KY, VA, WI, CO, CT, ME, MO, NV, NH). The BCBS brand carries decades of provider trust and member familiarity that single-state plans cannot match. Switching out of an Elevance BCBS plan typically means switching out of the BCBS network — a meaningful behavioral and clinical disruption for members.
- State Medicaid + Medicare Advantage Contracts: Elevance administers Medicaid managed care in many of its BCBS states under multi-year capitation contracts that require state-specific licensure, actuarial certification, and network adequacy compliance. Each contract represents 3-5 years of regulated revenue with built-in renewal mechanisms; exit is operationally and politically difficult. Medicare Advantage contracts add another federal-program embedding layer.
- Carelon: The Healthcare Services Build: Carelon (formerly IngenioRx + various M&A) is Elevance's pharmacy benefit, analytics, behavioral health, and post-acute services platform. Carelon Services and Carelon Rx now generate ~$60B+ of segment revenue and are growing faster than the legacy Health Benefits business. The strategy mirrors UNH's Optum playbook with a 5-7 year lag; the directional thesis is sound but execution risk is real.
- Claims Data on 47M+ Members: Decades of claims data across 47M+ medical members and additional pharmacy/dental/vision lives feed risk-adjustment models, care management programs, and underwriting. While the dataset is meaningfully smaller than UNH's 140M-member base, it is still a structural asset for population health analytics and value-based care contracting in BCBS states.
Moat Verdict
Elevance's lock is still BCBS exclusivity in 14 states, Medicaid contracts, and the provider network. Those are AI-resilient. The May stamp had every resilient pillar at strong and printed 100, which put a Blue-plan insurer next to Moody's. Proprietary data is intact (47M vs UNH 140M). Bundling is weakened (Carelon is a lag, not Optum). Moat 90 sits just under UNH at 91. Growth and valuation stay. Coverage only. Not a print restamp.
77.6 resilient · 56.9 vulnerable · 80/20 = 73.5 · = 73
Open a moat to read its note.
Provider portals, claims submission systems, and Carelon care-management workflows accumulate years of organizational learning across hospital systems, physician groups, and HR benefits teams. Switching adds material retraining cost across thousands of users.
Risk-adjustment models, actuarial pricing, network-adequacy algorithms and Carelon clinical-decision tools are tuned to Elevance's BCBS state populations and government-program rules. UnitedHealth, Cigna, Humana and Centene run the same kinds of models, and no figure shows Elevance's are better, so it rates intact.
Carelon uses some publicly available CMS and NIH datasets in its analytical products, but Elevance's data advantage is private claims data on 47M+ members, rated under proprietaryData. It never held a public-data-access moat, so the pillar is not applicable rather than weakened. Previously weakened.
Healthcare actuaries, BCBS-license-trained underwriters, and clinical informaticists are genuinely scarce. Elevance is one of the largest employers of MA-experienced actuaries in the US, though the talent base is smaller than UNH/Optum's.
Health Benefits + Carelon Rx + Carelon Behavioral + Carelon Services is a vertical build, not Optum. The card already called it a 5–7 year lag with execution risk. Employers and state agencies can still unbundle PBM, behavioral, and analytics. Directionally similar to UNH, not peer-equal.
47M+ medical members generate decades of claims data that power risk-adjustment and care-management analytics. That is a real dataset. It is not UNH's 140M-member base. Marked intact, not strong, so ELV does not sit above UNH on data gravity.
BCBS license exclusivity in 14 states is a brand-protected regulatory monopoly within those geographies — the BCBS Association's licensing framework restricts which entity can use the brand in each state, effectively granting Elevance a multi-decade BCBS franchise in its footprint. State Medicaid managed-care contracts add multi-year regulated revenue with high re-licensure barriers. Federal MA contracts add another layer.
Bilateral provider-employer network effects: Elevance's 1.7M+ provider relationships in BCBS states make it the broadest network for employers in those geographies, and providers cannot afford to be out-of-network for the dominant BCBS plan in their state. Decades of network compounding create real switching friction on both sides.
Carelon Rx, claims processing, utilization management and care coordination run inside employer, hospital, Medicaid and Medicare Advantage operations. Employers and states re-bid insurers on multi-year cycles, and no retention figure is on file, so it rates intact — the same rating UnitedHealth carries.
Elevance's claims systems are the record of member health and financial transactions across 47M+ lives, and Carelon's care-management and behavioral-health platforms hold clinical records in provider practices in BCBS states. But every insurer's claims system is the record for its own members; that is table stakes, not a record third parties reconcile against. UnitedHealth rates strong on this pillar because Change Healthcare's clearinghouse touches roughly one in three US patient records across payers; Elevance has no equivalent cross-payer position. Re-rated from strong to intact.
Blue plan membership concentration secures provider discounts in its states, but UnitedHealth runs a larger national book.
Franchise reputation matters but is inseparable from the regulatory standing and relationships rated elsewhere; not credited twice.
Moat in 5–10 years
Elevance's moats hold. The BCBS licence in 14 states and the provider network that comes with being the dominant local plan are franchise positions that MA rate pressure and reserve questions do not touch. Carelon's bundle stays weakened and is a 5-7 year build with no attach figure yet, so no widening is called.
No moat trending · 73 holds
Growth Analysis
Growth Drivers
Key Risk
If the Medicare Advantage risk-adjustment accrual (~$935M through Q3 2026) proves materially under-reserved, or Health Benefits margins stay near Q3's 1.0% into 2027 as Medicaid rates lag cost trend, the 12% growth target from the $26.75 baseline depends on Carelon alone and the 2027 guide disappoints.
Score Derivation
58.8 base − 1.3 trajectory − 4 margin − 5 risk = 48
Base 58.8 (2-5% revenue CAGR, midpoint 3.5%) − 1.3 trajectory (Carelon revenue decelerating from +7.9% to +6% to +5%; Health Benefits and Medicare Advantage stable) − 4 compressing margin (Health Benefits operating margin 1.0% in Q3 vs 1.4%, and 2.1% vs 3.8% in Q2; adjusted operating expense ratio +90bps in Q3) − 5 moderate MA risk-adjustment/CMS benchmark risk = 48
Price Scenarios (12–24 Months)
Price vs Targets
Dashed lines mark the 12–24 month bear, base and bull targets. Daily closes.
Valuation Multiples
| Trailing P/E (GAAP) | ~20× |
| Forward P/E (NTM) | ~15× |
| PEG Ratio | ~3.0× |
| Price / Sales (NTM) | ~0.4× |
| Price / FCF | ~12× |
ELV no longer screens as cheap as it did in May: about 15× the FY2026 adjusted guide and about 16× the recurring baseline, which strips out the year's non-operating gains. The upside case still rests on Carelon's margin expansion (4.7% in Q3 2026) and a Medicaid margin recovery in 2027, and the CMS risk-adjustment accrual could still be revised in either direction.
Approximate figures as of October 2026.
Where We Are vs Targets
Loading live price…
Medicare Advantage benchmarks are cut further in 2027, the $935M risk-adjustment accrual proves under-reserved, and Carelon margins disappoint relative to the Optum playbook.
- CMS imposes additional MA benchmark reductions of 3-5% in 2027, forcing Elevance to exit unprofitable MA markets and shrink the segment by 10%+ of members
- The Medicare Advantage risk-adjustment liability is settled at the high end of the disclosed range (+$565M above accrual) and a parallel DOJ-style investigation extends to Elevance's coding practices
- Carelon services growth decelerates to single digits as competitive pressure from Optum + CVS Caremark intensifies, leaving margin expansion below plan
- Multiple compresses to ~10× forward EPS as the stock trades on Health Benefits earnings alone with no Carelon premium
FY2026 adjusted EPS lands near the at-least-$29 guide, the 2027 target of at least 12% growth from the $26.75 baseline is met (about $30), Carelon keeps expanding margin, and the multiple holds around 14-15× forward.
- Adj. EPS reaches ~$29 in FY2026 with the MA risk-adjustment accrual resolved within the disclosed range
- Carelon revenue grows mid-single digits while its operating margin expands from 4.7% (Q3 2026) toward 6%
- Medicaid margins recover in 2027 from what management calls the 2026 trough as July rate updates catch up with cost trend
- FY2027 adjusted EPS of ~$30 at ~14-15×, with buybacks supporting per-share growth
Carelon scales toward Optum-comparable margins, MA returns to growth in 2027 after repricing, and Elevance re-rates to peer-leading multiples.
- Carelon Services + Rx reaches $80B+ in FY2027 with operating margins expanding toward 9-10% (closing half the gap to Optum), driving segment operating income above $7B
- Medicare Advantage member count returns to growth in 2027 as competitors retreat from unprofitable markets, allowing Elevance to expand share with disciplined pricing
- AI-powered claims and care management products from Carelon become licensed externally, opening a healthcare-services-as-a-platform revenue stream valued at premium multiples
- Multiple expands to ~18-19× forward EPS on FY2027 EPS of ~$30, with continued capital return providing additional total-return cushion
ELV: common questions
Is Elevance Health stock a buy?
We rate Elevance Health Avoid, with a composite score of 58/100: moat 73, growth 48 and valuation 63. The valuation score is struck against our bear, base and bull targets and moves with the price.
What is Elevance Health's moat?
Elevance Health scores 73/100 on moat. Elevance is the largest Blue Cross Blue Shield (BCBS) licensee in the US (14 states), giving it brand-protected, state-level managed care contracts that competitors cannot replicate.
How fast is Elevance Health expected to grow?
We estimate 2-5% a year over the next three to five years, for a growth score of 48/100.
What is Elevance Health's price target?
Our base case is $430, with $280 in the bear case and $560 in the bull case.